Login to Your Account

Amgen's in as Immatics closes $58M E round for T-cell therapies

By Cormac Sheridan
Staff Writer

Wednesday, October 4, 2017

DUBLIN – Immatics AG raised $58 million in a series E round that brought in Amgen Inc. as a new investor. The financing is confirmation that the German company remains at the front rank of Europe’s immuno-oncology firms.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription